上海医药硫酸艾沙康唑原料药获批上市

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of the active pharmaceutical ingredient Sulfate Isavuconazole for production by its subsidiary, Upjohn Kangli (Changzhou) Pharmaceutical Co., Ltd, by the National Medical Products Administration of China [1] Group 1: Company Information - The approved drug, Sulfate Isavuconazole, is a triazole antifungal agent and a prodrug of Isavuconazole, which is rapidly converted into its active metabolite in the body by plasma esterases [1] - The drug is developed in collaboration with Astellas Pharma and Basilea Pharmaceutica, and it was approved for use in the United States in 2015 for the treatment of invasive aspergillosis and mucormycosis in adults [1] Group 2: Industry Context - Isavuconazole works by inhibiting the biosynthesis of ergosterol, thereby disrupting the formation of fungal cell membranes, similar to other triazole antifungal agents [1]